Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and hymenialdisine

cyc 202 has been researched along with hymenialdisine in 2 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(hymenialdisine)		Trials
(hymenialdisine)		Recent Studies (post-2010) (hymenialdisine)
979739342019

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)hymenialdisine (IC50)
Serine/threonine-protein kinase Chk1Homo sapiens (human)1.925
Glycogen synthase kinase 3 Plasmodium falciparum 3D70.023
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.022
Serine/threonine-protein kinase Chk2Homo sapiens (human)0.042
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.006
Protein kinase C beta typeHomo sapiens (human)1.2
Cyclin-dependent kinase 1Homo sapiens (human)0.041
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.022
G2/mitotic-specific cyclin-BMarthasterias glacialis (spiny starfish)0.02
Protein kinase C alpha typeHomo sapiens (human)0.7
Glycogen synthase kinase-3 betaRattus norvegicus (Norway rat)0.02
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)0.009
Cyclin-A2Homo sapiens (human)0.07
G1/S-specific cyclin-E1Homo sapiens (human)0.04
Cyclin-dependent kinase 2Homo sapiens (human)0.055
Mitogen-activated protein kinase 1Homo sapiens (human)0.0075
Casein kinase I isoform deltaHomo sapiens (human)0.035
Glycogen synthase kinase-3 betaHomo sapiens (human)0.0267
Casein kinase II subunit alphaHomo sapiens (human)7
Cyclin-A1Homo sapiens (human)0.07
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.022
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)0.8373
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.0383
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.022
Mitogen-activated protein kinase kinase kinase 5Homo sapiens (human)3.575
Cyclin-dependent kinase 1Oryzias latipes (Japanese medaka)0.02

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Brady, HJ; Caldicott, A; Crescenzi, E; Dransfield, I; Duffin, R; Gray, M; Haslett, C; Martin, MC; Martinez-Losa, M; Riley, NA; Rossi, AG; Savill, JS; Sawatzky, DA; Sheldrake, TA; Walker, A; Walker, TR; Ward, C1

Other Studies

2 other study(ies) available for cyc 202 and hymenialdisine

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
    Nature medicine, 2006, Volume: 12, Issue:9

    Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Azepines; Carrageenan; Caspase 3; Cyclin-Dependent Kinases; Enzyme Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Inflammation; Male; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neutrophils; Pleurisy; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Roscovitine

2006